⚠️ Teaching Case Note: This case has been de-identified and reconstructed for educational purposes. Clinical details reflect real surgical decision-making and outcomes. Patient identity is fully protected.
Lung Tumor 3 mm From the Spinal Cord, Inoperable, COPD — Treated With Proton Therapy, Complete Metabolic Response at Three Months
He was 68 years old, a 40-year smoker with COPD and a history of coronary stenting. A 4.2 cm lung adenocarcinoma at the right hilum had grown to within 3 mm of his spinal cord and was inseparable from the esophageal wall. His diffusion capacity was 55% of predicted. He was American-Chinese, refused surgery, and wanted to preserve his lung function and quality of life.
Conventional photon radiotherapy — the standard treatment for inoperable stage IIIA lung cancer — could not deliver a curative dose to this tumor without exceeding spinal cord tolerance. The physics did not allow it.
Dr. Zhen Zhang's team at Fudan University Shanghai Cancer Center used pencil beam scanning intensity-modulated proton therapy (IMPT), with adaptive re-planning at week three and concurrent PD-1 immunotherapy. Six weeks of treatment. No radiation pneumonitis. Grade 1 esophagitis only. At three months: complete metabolic response on PET-CT. The patient was jogging.
The Problem: Ultra-Central Tumor, Spinal Cord at 3 mm, Failing Lungs
PET-CT showed the right upper lobe mass at 4.2 × 3.8 cm, SUVmax 18.5 — highly metabolically active. The tumor was classified as ultra-central: abutting the main bronchus, with the nearest point of the spinal cord at 3 mm and the esophageal wall boundary indistinct on MRI. Station 4R and 7 mediastinal nodes were enlarged and fused.
Bronchoscopic biopsy confirmed lung adenocarcinoma, acinar-predominant subtype. Molecular profiling: EGFR wild-type, ALK negative, PD-L1 TPS 30% — a meaningful immunotherapy target. Clinical staging: cT2bN2M0, Stage IIIA.
Pulmonary function defined the second constraint. FEV1 was 1.6 L (65% predicted); DLCO was 55% — significantly impaired diffusion capacity from decades of smoking and COPD. For conventional photon IMRT to cover the tumor and involved nodes, the mean lung dose (MLD) would exceed 15 Gy and the V20 (volume of lung receiving ≥20 Gy) would approach 35% — thresholds above which symptomatic radiation pneumonitis becomes probable in a patient with pre-existing COPD. The spinal cord maximum dose with photon planning was modeled at 48–50 Gy — above the 45 Gy tolerance limit for a 2 Gy/fraction schedule.
Conventional radiotherapy was not a safe option for this anatomy and this lung function. The tumor was in a location where photon physics created an irresolvable conflict between tumor dose and organ-at-risk tolerance.
The Treatment Decision: Proton Therapy as the Only Viable Curative Option
The multidisciplinary tumor board reviewed the case. Surgery had been declined. Chemotherapy alone for stage IIIA disease is palliative, not curative. The question was whether a curative radiation dose could be delivered safely to this specific anatomy.
The answer depended on physics. Proton beams deposit the majority of their energy at a defined depth — the Bragg peak — and then stop. Beyond the Bragg peak, dose falls to near zero. Photon beams, by contrast, deposit dose continuously along their path and exit the body on the far side. For a tumor 3 mm from the spinal cord, the difference between these two dose distributions is the difference between a treatable case and an untreatable one.
Dr. Zhang's team planned an IMPT approach using three beam angles — two posterior oblique fields and one anterior field — with the Bragg peaks positioned to terminate within the tumor volume, placing the steep dose falloff between the tumor's posterior margin and the spinal cord. Robustness optimization was applied: the plan was stress-tested against simulated setup errors of ±3 mm and respiratory motion uncertainties, confirming that spinal cord maximum dose remained below 30 Gy under all modeled scenarios.
Concurrent PD-1 inhibitor immunotherapy was added as a radiosensitizer and systemic agent, targeting the PD-L1 TPS 30% expression and the potential for an abscopal immune response to high-dose focal irradiation.
The Treatment: Six Weeks of Precision Proton Delivery
Simulation and planning. Four-dimensional CT (4D-CT) simulation captured the full respiratory motion envelope, defining the internal target volume (ITV) that encompassed tumor position across all breathing phases. PET-CT and high-resolution MRI were fused to the planning CT, allowing the biological target volume (BTV) — the metabolically active tumor core — to be delineated separately from the anatomical gross tumor volume. This multimodal fusion ensured that the highest-dose region of the proton plan was aligned with the highest-risk tumor biology.
Dose prescription. 60 GyE in 30 fractions (conventional fractionation) to the primary tumor and involved mediastinal nodes. Involved nodal stations (4R, 7) received a simultaneous integrated boost to 66 GyE. Spinal cord maximum dose: 28 GyE. Mean lung dose: 8.5 GyE. Heart V30: 12%.
Daily image guidance. Before each fraction, cone-beam CT (CBCT) was acquired and automatically registered to bony landmarks and implanted fiducial markers. Residual setup error was corrected to below 1 mm before beam delivery. This level of positional accuracy is required for proton therapy — the Bragg peak position is sensitive to density changes along the beam path, and millimeter-level errors in patient positioning translate directly into dose distribution errors.
Respiratory gating. Treatment was delivered during the exhale phase of the respiratory cycle, using real-time respiratory monitoring to gate beam delivery. Gating reduced the ITV margin by 4 mm in the superior-inferior direction compared to free-breathing delivery, reducing the volume of normal lung included in the high-dose region.
Adaptive re-planning at fraction 15. Mid-treatment CT at week three showed the primary tumor had reduced in volume by approximately 35%, and the patient had lost 3 kg of body weight — both changes that alter the density map along the proton beam paths and shift the Bragg peak positions relative to the original plan. A new CT simulation was performed and the proton plan was reoptimized. Without re-planning, the original plan would have delivered underdose to the tumor periphery and potential overdose to the esophagus as the tumor shrank away from its original position. Adaptive re-planning corrected both risks.
Treatment duration: 6 weeks, 30 fractions.
Toxicity and Response
Acute toxicity during treatment was minimal. Esophagitis reached CTCAE Grade 1 — mild swallowing discomfort, no analgesic requirement, no treatment interruption. Radiation pneumonitis: Grade 0 throughout treatment and follow-up. Hematological toxicity: Grade 2 leukopenia, managed with supportive care, no dose reduction required. No spinal cord symptoms at any point.
At treatment completion: CEA had normalized. Enhanced CT showed 60% reduction in tumor volume with decreased density — radiological evidence of central necrosis.
At three months post-treatment: PET-CT demonstrated complete metabolic response (CMR) — no residual FDG-avid activity in the primary tumor or mediastinal nodes. FEV1 was stable at 1.6 L, unchanged from baseline — confirming that the proton plan's lung-sparing design had protected the already-compromised pulmonary function. The patient reported no significant cough or dyspnea and had resumed light jogging.
Expert Commentary — Dr. Zhen Zhang
"Ultra-central lung cancer — tumors abutting the proximal bronchial tree, with the spinal cord or esophagus within millimeters of the target — represents the anatomical limit of what photon radiotherapy can safely treat. The physics of photon beams creates an irresolvable conflict: to cover the tumor, you must irradiate the cord. To protect the cord, you must underdose the tumor. There is no photon plan that resolves this conflict for a tumor at 3 mm.
Proton therapy resolves it through physics, not technique. The Bragg peak stops. The dose beyond it is near zero. For this patient, that physical property was the difference between a curative treatment and a palliative one. We placed the Bragg peak at the posterior tumor margin. The spinal cord received 28 GyE. The tumor received 60 GyE. That dose differential — more than 2:1 — is not achievable with photons in this geometry.
The adaptive re-planning at fraction 15 is not optional in lung cancer proton therapy — it is mandatory. Lung tumors change. Patients lose weight. The density map along the beam path changes with every kilogram lost and every centimeter of tumor regression. A proton plan optimized on day one is not the plan being delivered on day 21 if you do not re-image and reoptimize. The re-planning added one week of planning time and protected the entire six weeks of treatment investment.
The complete metabolic response at three months is the outcome we planned for. This patient refused surgery. He had COPD. He had a tumor that photon radiotherapy could not safely treat. Proton therapy gave him a curative option that did not exist for him anywhere that lacked this technology. That is what precision radiotherapy means — not just better dose distributions, but treatments that are possible where they were previously impossible."
About Dr. Zhen Zhang
Dr. Zhen Zhang is a leading radiation oncologist at Fudan University Shanghai Cancer Center, specializing in stereotactic body radiotherapy (SBRT) and intensity-modulated radiation therapy (IMRT) for lung, liver, and head-neck cancers. He has pioneered proton therapy protocols for complex solid tumors in China and is widely regarded as one of Shanghai's foremost experts in precision radiotherapy for international oncology patients. Dr. Zhang is a recognized advocate for the integration of immunotherapy with high-dose focal radiation in locally advanced disease.
How CMCS Supported This Patient
China Medical Concierge – Shanghai (CMCS) coordinated the full care pathway for this American-Chinese patient: specialist matching and priority access to Dr. Zhang's team at Fudan University Shanghai Cancer Center, multidisciplinary tumor board coordination across radiation oncology, medical oncology, and pulmonology, full English-language communication throughout — including treatment planning consultations, informed consent for concurrent proton-immunotherapy, and weekly on-treatment review meetings — coordination of the mid-treatment adaptive re-planning process, and post-treatment follow-up including PET-CT scheduling, pulmonary function testing, and immunotherapy continuation planning.
For international patients and expatriates in Shanghai facing locally advanced or anatomically complex cancers — where the choice of radiation modality, treatment planning precision, and adaptive management during treatment determines both tumor control and long-term organ function — CMCS provides end-to-end support from initial staging to post-treatment surveillance.
📧 contract@medicalsh.com | 📱 WhatsApp | 🌐 medicalsh.com
0 則留言